{"id":"mk0653-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1138","moleculeType":"Small molecule","molecularWeight":"409.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezetimibe selectively binds to NPC1L1, a sterol transporter located on the brush border of the small intestine, preventing the uptake of dietary and biliary cholesterol. This reduces intestinal cholesterol absorption and leads to decreased plasma LDL cholesterol levels. The mechanism is distinct from statins, making ezetimibe useful as monotherapy or in combination with other lipid-lowering agents.","oneSentence":"Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:45.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (primary and secondary)"},{"name":"Homozygous familial hypercholesterolemia"},{"name":"Heterozygous familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT00092560","phase":"PHASE3","title":"Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Hypercholesterolemia, Hypertriglyceridemia","enrollment":587},{"nctId":"NCT00651963","phase":"PHASE4","title":"Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Lipid Metabolism Disorder","enrollment":80},{"nctId":"NCT00653276","phase":"PHASE1","title":"MD Ezetimibe Cyclosporine Interaction (0653-057)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-11","conditions":"Cholesterol","enrollment":13},{"nctId":"NCT00092586","phase":"PHASE3","title":"Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":2904},{"nctId":"NCT00652847","phase":"PHASE4","title":"Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia","enrollment":1140},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00551876","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":214},{"nctId":"NCT00551447","phase":"PHASE3","title":"A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01","conditions":"Coronary Disease","enrollment":616},{"nctId":"NCT00457275","phase":"PHASE3","title":"Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":440},{"nctId":"NCT00092820","phase":"PHASE3","title":"Sitosterolemia Extension Study (0653-004)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-12","conditions":"Lipid Metabolism, Inborn Errors, Heart Disease","enrollment":58},{"nctId":"NCT00092638","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":450},{"nctId":"NCT00092625","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":442},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00157911","phase":"PHASE3","title":"A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Hypercholerolemia","enrollment":136},{"nctId":"NCT00092807","phase":"PHASE3","title":"Sitosterolemia Extension Study (0653-003)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-12","conditions":"Lipid Metabolism, Inborn Errors, Heart Disease","enrollment":37},{"nctId":"NCT00652301","phase":"PHASE3","title":"A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-07","conditions":"Cholesterol","enrollment":40},{"nctId":"NCT00092898","phase":"PHASE3","title":"An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-10","conditions":"Lipid Metabolism, Inborn Errors, Heart Disease","enrollment":30},{"nctId":"NCT00092612","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":372},{"nctId":"NCT00092833","phase":"PHASE3","title":"Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2002-07","conditions":"Hypercholesterolemia, Familial, Lipid Metabolism, Inborn Errors","enrollment":49},{"nctId":"NCT00092599","phase":"PHASE3","title":"Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":410},{"nctId":"NCT00328523","phase":"PHASE3","title":"TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Hypercholesterolaemia, Hyperlipidaemia","enrollment":1496},{"nctId":"NCT00092573","phase":"PHASE3","title":"Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04","conditions":"Hypercholesterolemia, Hypertriglyceridemia","enrollment":576},{"nctId":"NCT00101439","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11-10","conditions":"Hypercholesterolemia","enrollment":58},{"nctId":"NCT01611883","phase":"PHASE4","title":"A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-07-02","conditions":"Hypercholesterolemia","enrollment":152},{"nctId":"NCT00867165","phase":"PHASE3","title":"Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-05-21","conditions":"Primary Hypercholesterolemia","enrollment":138},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT03882892","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-02","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT00395473","phase":"PHASE3","title":"Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03","conditions":"Hypercholesterolemia","enrollment":141},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT03882996","phase":"PHASE3","title":"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-06","conditions":"Hypercholesterolemia","enrollment":432},{"nctId":"NCT00753883","phase":"PHASE4","title":"Ezetrol Post-Marketing Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hyperlipidemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4890,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0653, ezetimibe","genericName":"MK0653, ezetimibe","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter. Used for Hypercholesterolemia (primary and secondary), Homozygous familial hypercholesterolemia, Heterozygous familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}